Regeneron (REGN) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$15.5B

Revenue (quarter)

$4.3B

Revenue growth (year over year)

+16.73%

Gross profit (trailing twelve months)

$13.2B

Gross margin

84.86%

Net income (trailing twelve months)

$4.3B

Net income (quarter)

$1.3B

Net income growth (year over year)

−6.81%

Net margin

27.86%

Return on equity

14.04%

EPS (trailing twelve months)

$41.87

Book value per share

$306.69

P/E (trailing twelve months)

18.51

Price to book

2.53

Debt to assets

24.01%

Payout ratio

8.37%

Dividend yield

0.48%

Company profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

• Is Regeneron (REGN) profitable?

  Yes. Regeneron earned $4.3B in net income over the trailing twelve months, a net margin of 27.86%.

• How much revenue does Regeneron (REGN) make?

  Regeneron generated $15.5B in revenue over the trailing twelve months, up 16.73% year over year.

• What is REGN's P/E ratio?

  Regeneron trades at 18.5 times trailing twelve-month earnings, on an EPS of $41.87.

• How do I buy stock in Regeneron (REGN)?

  REGN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.